The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
作者信息
Archer David F
出版信息
Menopause. 2011 Jan;18(1):6-7. doi: 10.1097/gme.0b013e318203a46b.
PMID:21173718
Abstract
摘要
相似文献
1
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Menopause. 2011 Jan;18(1):6-7. doi: 10.1097/gme.0b013e318203a46b.
2
Another selective estrogen-receptor modulator for osteoporosis.
N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.
3
Lasofoxifene for postmenopausal women with osteoporosis.
N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9.
4
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Clin Calcium. 2004 Oct;14(10):85-93.
5
Not all SERMs are created equal.
Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.
6
Lasofoxifene in postmenopausal women with osteoporosis.
N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.
7
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Menopause. 2010 May-Jun;17(3):642-53. doi: 10.1097/gme.0b013e3181c4f1d6.
8
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f.
9
Use of SERMs for treatment in postmenopausal women.
J Steroid Biochem Mol Biol. 2014 Jul;142:142-54. doi: 10.1016/j.jsbmb.2013.12.011. Epub 2013 Dec 25.
10
Lasofoxifene for postmenopausal women with osteoporosis.
N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.
引用本文的文献
1
Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.
Front Immunol. 2022 Jul 6;13:889950. doi: 10.3389/fimmu.2022.889950. eCollection 2022.
2
Selective Estrogen Receptor Modulators.
Asian Spine J. 2016 Aug;10(4):787-91. doi: 10.4184/asj.2016.10.4.787. Epub 2016 Aug 16.
Zotero 插件